Biogen (BIIB) Shares Outstanding (Diluted) (2009 - 2026)
Biogen (BIIB) Shares Outstanding (Diluted) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Dil.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 2.44 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.77 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 2.47 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.91 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 1.56 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 544.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 1.24 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 5.70 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 2.06 Bn |
| 10 | Biogen | 32.04 Bn | 30.76 Bn | 1.96 Bn | 148.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 148.70 Mn |
| Mar 31, 2026 | 148.40 Mn |
| Dec 31, 2025 | 147.10 Mn |
| Sep 30, 2025 | 147.10 Mn |
| Jun 30, 2025 | 146.70 Mn |
| Mar 31, 2025 | 146.60 Mn |
| Dec 31, 2024 | 145.90 Mn |
| Sep 30, 2024 | 146.10 Mn |
| Jun 30, 2024 | 145.90 Mn |
| Mar 31, 2024 | 145.90 Mn |
| Dec 31, 2023 | 145.60 Mn |
| Sep 30, 2023 | 144.80 Mn |
| Jun 30, 2023 | 145.50 Mn |
| Mar 31, 2023 | 145.20 Mn |
| Dec 31, 2022 | 146.00 Mn |
| Sep 30, 2022 | 144.80 Mn |
| Jun 30, 2022 | 146.20 Mn |
| Mar 31, 2022 | 147.60 Mn |
| Dec 31, 2021 | 149.60 Mn |
| Sep 30, 2021 | 148.60 Mn |